In a recent article with The Conversation, Dr @dr-jamesbrown.bsky.social , member of the LDCRC leadership team, shares how patient voices challenge researchers to think differently and ensure real-world impact through PPI Limerick Cancer Research.

I would think that more effective treatments (used on groups of patients that have been profiled to know it will work on them, or used in improved settings like neoadjuvant) will ultimately create long-term savings and improve cost-effectiveness- but we need more studies to confirm.

Thank you, it really highlights that not only is neoadjuvant treatment clinically effective, it is also increasingly cost effective. It also highlights the growing cost of treating older patients, an important consideration for healthcare systems with (worldwide) aging populations.